Table 3 Adjusted sub-distribution hazard ratios for developing atrial fibrillation by cancer treatment type among breast cancer surgery survivors
From: Mid- and long-term risk of atrial fibrillation among breast cancer surgery survivors
| Â | Treatment type | Subjects (N) | Case (n) | IR per 1000 PYs | Model 1 (Crude) sHR (95% CI) | Model 2 sHR (95% CI) | Model 3 sHR (95% CI) | Model 4 sHR (95% CI) | |
|---|---|---|---|---|---|---|---|---|---|
Main analysis | Anthracyclines | No | 54,523 | 591 | 2.14 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
Yes | 58,709 | 575 | 1.89 | 0.88 (0.79–0.98) | 1.39 (1.23–1.58) | 1.39 (1.23–1.57) | 1.57 (1.28–1.92) | ||
Taxane | No | 48,092 | 530 | 2.17 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |
Yes | 65,140 | 636 | 1.89 | 0.87 (0.77–0.97) | 1.22 (1.08–1.37) | 1.20 (1.06–1.35) | 0.84 (0.69–1.02) | ||
Trastuzumab | No | 96,287 | 996 | 2.00 | 1(Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |
Yes | 16,945 | 170 | 2.04 | 1.03 (0.87–1.21) | 1.15 (0.97–1.35) | 1.11 (0.94–1.30) | 0.96 (0.80–1.14) | ||
Endocrine therapy | No | 35,307 | 386 | 2.19 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |
Tamoxifen | 49,574 | 294 | 1.12 | 0.51 (0.44–0.59) | 0.79 (0.68–0.92) | 0.78 (0.67–0.92) | 0.81 (0.70–0.95) | ||
AIs | 27,046 | 471 | 3.46 | 1.58 (1.38–1.81) | 1.01 (0.88–1.15) | 1.00 (0.87–1.15) | 1.00 (0.87–1.15) | ||
Both | 1305 | 15 | 2.23 | 1.02 (0.61–1.70) | 0.70 (0.42–1.17) | 0.66 (0.40–1.11) | 0.68 (0.41–1.14) | ||
Radiation therapy | No | 34,156 | 433 | 2.52 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |
Yes | 79,076 | 733 | 1.79 | 0.71 (0.63–0.80) | 1.01 (0.89–1.14) | 1.02 (0.90–1.16) | 0.98 (0.87–1.12) | ||
3-year landmark analysis | Anthracyclines | No | 52,036 | 390 | 2.32 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
Yes | 55,117 | 387 | 2.04 | 0.88 (0.76–1.01) | 1.41 (1.22–1.64) | 1.40 (1.21–1.63) | 1.48 (1.16–1.90) | ||
Taxane | No | 45,695 | 345 | 2.31 | 1 (Ref.) | 1(Ref.) | 1 (Ref.) | 1 (Ref.) | |
Yes | 61,458 | 432 | 2.07 | 0.90 (0.78–1.03) | 1.27 (1.10–1.48) | 1.25 (1.08–1.45) | 0.91 (0.72–1.16) | ||
Trastuzumab | No | 91,190 | 663 | 2.15 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |
Yes | 15,963 | 114 | 2.28 | 1.07 (0.88–1.30) | 1.19 (0.98–1.46) | 1.16 (0.95–1.41) | 0.99 (0.80–1.23) | ||
Endocrine therapy | No | 32,452 | 252 | 2.34 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |
Tamoxifen | 47,839 | 208 | 1.27 | 0.54 (0.45–0.65) | 0.85 (0.70–1.03) | 0.85 (0.70–1.02) | 0.89 (0.74–1.08) | ||
AIs | 25,633 | 308 | 3.72 | 1.59 (1.35–1.88) | 0.99 (0.84–1.18) | 0.99 (0.83–1.17) | 0.99 (0.83–1.17) | ||
Both | 1229 | 9 | 2.16 | 0.92 (0.47–1.79) | 0.62 (0.32–1.21) | 0.59 (0.30–1.14) | 0.61 (0.31–1.18) | ||
Radiation therapy | No | 31,842 | 283 | 2.70 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |
Yes | 75,311 | 494 | 1.95 | 0.72 (0.62–0.84) | 1.04 (0.89–1.21) | 1.05 (0.90–1.22) | 1.01 (0.87–1.18) | ||
5-year landmark analysis | Anthracyclines | No | 34,664 | 183 | 2.32 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
Yes | 39,965 | 205 | 2.20 | 0.95 (0.78–1.16) | 1.57 (1.27–1.94) | 1.56 (1.26–1.93) | 1.56 (1.10–2.21) | ||
Taxane | No | 31,154 | 160 | 2.28 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |
Yes | 43,475 | 228 | 2.24 | 0.98 (0.80–1.20) | 1.43 (1.16–1.76) | 1.40 (1.14–1.73) | 1.02 (0.72–1.43) | ||
Trastuzumab | No | 64,089 | 332 | 2.22 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |
Yes | 10,540 | 56 | 2.45 | 1.11 (0.84–1.47) | 1.24 (0.93–1.65) | 1.20 (0.90–1.59) | 1.01 (0.75–1.37) | ||
Endocrine therapy | No | 22,325 | 115 | 2.23 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |
Tamoxifen | 34,191 | 116 | 1.46 | 0.65 (0.50–0.84) | 1.04 (0.80–1.35) | 1.04 (0.80–1.35) | 1.13 (0.86–1.48) | ||
AIs | 17,253 | 152 | 3.89 | 1.74 (1.37–2.22) | 1.07 (0.83–1.36) | 1.06 (0.83–1.36) | 1.08 (0.84–1.38) | ||
Both | 860 | 5 | 2.49 | NA | NA | NA | NA | ||
Radiation therapy | No | 21,464 | 144 | 2.86 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | |
Yes | 53,165 | 244 | 2.00 | 0.70 (0.57–0.86) | 1.02 (0.82–1.26) | 1.03 (0.83–1.28) | 0.98 (0.79–1.22) | ||